France Diabetes Drugs and Devices Market Size- By Drug, By Device- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

France Diabetes Drugs and Devices Market Introduction and Overview

According to SPER market research, 'France Diabetes Drugs and Devices Market Size - By Drug, By Device - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the France Diabetes Drugs and Devices Market is predicted to reach USD 1.99 billion by 2033 with a CAGR of 2.63%.

The purpose of diabetic medications is to stabilise and regulate blood glucose levels in individuals with the disease. Patients with diabetes who have contracted SARS-CoV-2 infection may benefit from treatment with diabetic medications. Diabetes medications lower blood glucose levels in the body, which helps treat diabetes mellitus type 1 and type 2. Diabetes type 2, often known as adult-onset diabetes or non-insulin-dependent diabetes, is a disorder in which the body uses insulin poorly.

Global sales of the product were significantly impacted by the COVID-19 epidemic. Worldwide implementation of government lockdowns reduced the number of patients seeking diagnosis and treatment from healthcare facilities like hospitals and pathology labs. However, the COVID-19 recovery in 2021 led to a rise in hospital admissions and diabetes diagnoses, which raised the general public's demand for these drugs.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Drug, By Device

Regions covered Eastern, Western, Northern, Southern

Companies Covered Novo Nordisk, Sanofi, Eli Lilly, Biocon, Medtronic, Ypsomed, Becton Dickinson.

France Diabetes Drugs and Devices Market Segmentation:

By Drug: Based on the Drug, France Diabetes Drugs and Devices Market is segmented as; Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulin.

By Device: Based on the Device, France Diabetes Drugs and Devices Market is segmented as; Insulin Pumps, Insulin Pens, Insulin Syringes, Insulin Jet Injectors.

By Region: This research includes data for Eastern, Western, Northern, Southern.

Product Code: MEDE2434

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the France Diabetes Drugs and Devices Market

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. France Diabetes Drugs and Devices Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in France Diabetes Drugs and Devices Market

7. France Diabetes Drugs and Devices Market, By Drug (USD Million) 2020-2033

7.1. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Drug, 2020-2026
7.2. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Drug, 2027-2033
7.3. Basal or Long-acting Insulins
- 7.3.1. Lantus (Insulin Glargine)
- 7.3.2. Levemir (Insulin Detemir)
- 7.3.3. Toujeo (Insulin Glargine)
- 7.3.4. Tresiba (Insulin Degludec)
- 7.3.5. Basaglar (Insulin Glargine)
7.4. Bolus or Fast-acting Insulins
- 7.4.1. NovoRapid/Novolog (Insulin aspart)
- 7.4.2. Humalog (Insulin lispro)
- 7.4.3. Apidra (Insulin glulisine)
- 7.4.4. FIASP (Insulin aspart)
- 7.4.5. Admelog (Insulin lispro Sanofi)
7.5. Traditional Human Insulins
- 7.5.1. Novolin/Mixtard/Actrapid/Insulatard
- 7.5.2. Humulin
- 7.5.3. Insuman
7.6. Combination Insulins
- 7.6.1. NovoMix (Biphasic Insulin aspart)
- 7.6.2. Ryzodeg (Insulin degludec and Insulin aspart)
- 7.6.3. Xultophy (Insulin degludec and Liraglutide)
- 7.6.4. Soliqua/Suliqua (Insulin glargine and Lixisenatide)
7.7. Biosimilar Insulins
- 7.7.1. Insulin Glargine Biosimilars
- 7.7.2. Human Insulin Biosimilars

8. France Diabetes Drugs and Devices Market, By Device (USD Million) 2020-2033

8.1. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Device, 2020-2026
8.2. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Device, 2027-2033
8.3. Insulin Pumps
- 8.3.1. Insulin Pump Devices
- 8.3.2. Insulin Pump Reservoirs
- 8.3.3. Insulin Infusion sets
8.4. Insulin Pens
- 8.4.1. Cartridges in reusable pens
- 8.4.2. Disposable insulin pens
8.5. Insulin Syringes
8.6. Insulin Jet Injectors

9. France Diabetes Drugs and Devices Market Forecast, 2020-2033 (USD Million)

9.1. France Diabetes Drugs and Devices Market Size and Market Share

10. France Diabetes Drugs and Devices Market, By Region, 2020-2033 (USD Million)

10.1. France Diabetes Drugs and Devices Market Size and Market Share By Region (2020-2026)
10.2. France Diabetes Drugs and Devices Market Size and Market Share By Region (2027-2033)
10.3. Eastern
10.4. Western
10.5. Northern
10.6. Southern

11. Company Profile

11.1. Novo Nordisk
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. Sanofi
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. Eli Lilly
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. Biocon
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. Medtronic
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. Ypsomed
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. Becton Dickinson
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. Others